and equipment 9,272,415 5,157,163
------------ ------------
31,295,699 22,921,634
------------ ------------
------------ ------------
Liabilities
Current liabilities
Accounts payable and accrued liabilities 1,875,397 1,356,018
Repayable advances - 85,640
Current portion of long-term debt 629,479 746,658
------------ ------------
2,504,876 2,188,316
Deferred cost recoveries 286,596 84,203
Long-term debt 759,568 1,337,445
------------ ------------
3,551,040 3,609,964
------------ ------------
------------ ------------
Shareholders' Equity
Capital stock 70,396,170 48,302,036
Warrants 6,180,690 6,274,716
Contributed surplus 7,326,962 5,475,404
Deficit (56,159,163) (40,740,486)
------------ ------------
27,744,659 19,311,670
------------ ------------
31,295,699 22,921,634
'/>"/>
SOURCE SemBioSys Genetics Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1.
SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil2.
SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office3.
SemBioSys to present at the 10th Annual BIO CEO & Investor Conference4.
SemBioSys signs option agreement for safflower-produced food ingredient5.
SemBioSys announces 2007 third quarter results6.
SemBioSys to present insulin data at the Seventh Annual Diabetes Technology Meeting7.
SemBioSys updates Apo AI development program8.
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research9.
Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management10.
BioMed Realty Trust Announces Increase in Quarterly Common Stock Dividend11.
Emisphere Technologies, Inc. Announces Conference Call for 2007 Fourth Quarter and Year End Financial Results